Transcriptional regulation by iron of genes encoding iron- and manganese-superoxide dismutases from Pseudomonas putida.

Y. Kim,C. D. Miller,A. Anderson

DOI: https://doi.org/10.1016/S0378-1119(99)00369-8

IF: 3.913

1999-10-18

Gene

Abstract:

What problem does this paper attempt to address?

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

Dipika Sur,Anna Lena Lopez,Suman Kanungo,Allison Paisley,Byomkesh Manna,Mohammad Ali,Swapan K Niyogi,Jin Kyung Park,Banawarilal Sarkar,Mahesh K Puri,Deok Ryun Kim,Jacqueline L Deen,Jan Holmgren,Rodney Carbis,Raman Rao,Nguyen Thu Van,Allan Donner,Nirmal K Ganguly,G Balakrish Nair,Sujit K Bhattacharya,John D Clemens

DOI: https://doi.org/10.1016/s0140-6736(09)61297-6

IF: 202.731

2009-11-01

The Lancet

Abstract:BACKGROUND: Oral cholera vaccines consisting of killed whole cells have been available for many years, but they have not been used extensively in populations with endemic disease. An inexpensive, locally produced oral killed-whole-cell vaccine has been used in high-risk areas in Vietnam. To expand the use of this vaccine, it was modified to comply with WHO standards. We assessed the efficacy and safety of this modified vaccine in a population with endemic cholera.METHODS: In this double-blind trial, 107 774 non-pregnant residents of Kolkata, India, aged 1 year or older, were cluster-randomised by dwelling to receive two doses of either modified killed-whole-cell cholera vaccine (n=52 212; 1966 clusters) or heat-killed Escherichia coli K12 placebo (n=55 562; 1967 clusters), both delivered orally. Randomisation was done by computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for the patient to seek treatment in a health-care facility. We undertook an interim, per-protocol analysis at 2 years of follow-up that included individuals who received two completely ingested doses of vaccine or placebo. We assessed first episodes of cholera that occurred between 14 days and 730 days after receipt of the second dose. This study is registered with ClinicalTrials.gov, number NCT00289224.FINDINGS: 31 932 participants assigned to vaccine (1721 clusters) and 34 968 assigned to placebo (1757 clusters) received two doses of study treatment. There were 20 episodes of cholera in the vaccine group and 68 episodes in the placebo group (protective efficacy 67%; one-tailed 99% CI, lower bound 35%, p<0.0001). The vaccine protected individuals in age-groups 1.0-4.9 years, 5.0-14.9 years, and 15 years and older, and protective efficacy did not differ significantly between age-groups (p=0.28). We recorded no vaccine-related serious adverse events.INTERPRETATION: This modified killed-whole-cell oral vaccine, compliant with WHO standards, is safe, provides protection against clinically significant cholera in an endemic setting, and can be used in children aged 1.0-4.9 years, who are at highest risk of developing cholera in endemic settings.FUNDING: Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, Governments of South Korea, Sweden, and Kuwait.

medicine, general & internal
Efficacy of a Low-Cost, Inactivated Whole-Cell Oral Cholera Vaccine: Results from 3 Years of Follow-Up of a Randomized, Controlled Trial

Dipika Sur,Suman Kanungo,Binod Sah,Byomkesh Manna,Mohammad Ali,Allison M. Paisley,Swapan K. Niyogi,Jin Kyung Park,Banawarilal Sarkar,Mahesh K. Puri,Deok Ryun Kim,Jacqueline L. Deen,Jan Holmgren,Rodney Carbis,Raman Rao,Nguyen Thu Van,Seung Hyun Han,Stephen Attridge,Allan Donner,Nirmal K. Ganguly,Sujit K. Bhattacharya,G. Balakrish Nair,John D. Clemens,Anna Lena Lopez

DOI: https://doi.org/10.1371/journal.pntd.0001289

2011-10-18

PLoS Neglected Tropical Diseases

Abstract:BACKGROUND: Killed oral cholera vaccines (OCVs) have been licensed for use in developing countries, but protection conferred by licensed OCVs beyond two years of follow-up has not been demonstrated in randomized, clinical trials.METHODS/PRINCIPAL FINDINGS: We conducted a cluster-randomized, placebo-controlled trial of a two-dose regimen of a low-cost killed whole cell OCV in residents 1 year of age and older living in 3,933 clusters in Kolkata, India. The primary endpoint was culture-proven Vibrio cholerae O1 diarrhea episodes severe enough to require treatment in a health care facility. Of the 66,900 fully dosed individuals (31,932 vaccinees and 34,968 placebo recipients), 38 vaccinees and 128 placebo-recipients developed cholera during three years of follow-up (protective efficacy 66%; one-sided 95%CI lower bound = 53%, p<0.001). Vaccine protection during the third year of follow-up was 65% (one-sided 95%CI lower bound = 44%, p<0.001). Significant protection was evident in the second year of follow-up in children vaccinated at ages 1-4 years and in the third year in older age groups.CONCLUSIONS/SIGNIFICANCE: The killed whole-cell OCV conferred significant protection that was evident in the second year of follow-up in young children and was sustained for at least three years in older age groups. Continued follow-up will be important to establish the vaccine's duration of protection.TRIAL REGISTRATION: ClinicalTrials.gov NCT00289224.

tropical medicine,parasitology
Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India

Thomas F. Wierzba,Shantanu K. Kar,Vijayalaxmi V. Mogasale,Anna S. Kerketta,Young Ae You,Prameela Baral,Hemant K. Khuntia,Mohammad Ali,Yang Hee Kim,Shyam Bandhu Rath,Anuj Bhattachan,Binod Sah

DOI: https://doi.org/10.1016/j.vaccine.2015.03.073

IF: 4.169

2015-05-01

Vaccine

Abstract:BACKGROUND: A clinical trial conducted in India suggests that the oral cholera vaccine, Shanchol, provides 65% protection over five years against clinically-significant cholera. Although the vaccine is efficacious when tested in an experimental setting, policymakers are more likely to use this vaccine after receiving evidence demonstrating protection when delivered to communities using local health department staff, cold chain equipment, and logistics.METHODS: We used a test-negative, case-control design to evaluate the effectiveness of a vaccination campaign using Shanchol and validated the results using a cohort approach that addressed disparities in healthcare seeking behavior. The campaign was conducted by the local health department using existing resources in a cholera-endemic area of Puri District, Odisha State, India. All non-pregnant residents one year of age and older were offered vaccine. Over the next two years, residents seeking care for diarrhea at one of five health facilities were asked to enroll following informed consent. Cases were patients seeking treatment for laboratory-confirmed V. cholera-associated diarrhea. Controls were patients seeking treatment for V. cholerae negative diarrhea.RESULTS: Of 51,488 eligible residents, 31,552 individuals received one dose and 23,751 residents received two vaccine doses. We identified 44 V. cholerae O1-associated cases and 366 non V. cholerae diarrhea controls. The adjusted protective effectiveness for persons receiving two doses was 69.0% (95% CI: 14.5% to 88.8%), which is similar to the adjusted estimates obtained from the cohort approach. A statistical trend test suggested a single dose provided a modicum of protection (33%, test for trend, p=0.0091).CONCLUSION: This vaccine was found to be as efficacious as the results reported from a clinical trial when administered to a rural population using local health personnel and resources. This study provides evidence that this vaccine should be widely deployed by public health departments in cholera endemic areas.

immunology,medicine, research & experimental
Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial

Firdausi Qadri,Mohammad Ali,Fahima Chowdhury,Ashraful Islam Khan,Amit Saha,Iqbal Ansary Khan,Yasmin A Begum,Taufiqur R Bhuiyan,Mohiul Islam Chowdhury,Jasim Uddin,Jahangir A M Khan,Atique Iqbal Chowdhury,Anisur Rahman,Shah Alam Siddique,Muhammad Asaduzzaman,Afroza Akter,Arifuzzaman Khan,Young Ae You,Ashraf Uddin Siddik,Nirod Chandra Saha,Alamgir Kabir,Baizid Khoorshid Riaz,Shwapon Kumar Biswas,Farzana Begum,Leanne Unicomb,Stephen P Luby,Alejandro Cravioto,John D Clemens,Md Jasim Uddin

DOI: https://doi.org/10.1016/s0140-6736(15)61140-0

IF: 202.731

2015-10-01

The Lancet

Abstract:BACKGROUND: Cholera is endemic in Bangladesh with epidemics occurring each year. The decision to use a cheap oral killed whole-cell cholera vaccine to control the disease depends on the feasibility and effectiveness of vaccination when delivered in a public health setting. We therefore assessed the feasibility and protective effect of delivering such a vaccine through routine government services in urban Bangladesh and evaluated the benefit of adding behavioural interventions to encourage safe drinking water and hand washing to vaccination in this setting.METHODS: We did this cluster-randomised open-label trial in Dhaka, Bangladesh. We randomly assigned 90 clusters (1:1:1) to vaccination only, vaccination and behavioural change, or no intervention. The primary outcome was overall protective effectiveness, assessed as the risk of severely dehydrating cholera during 2 years after vaccination for all individuals present at time of the second dose. This study is registered with ClinicalTrials.gov, number NCT01339845.FINDINGS: Of 268,896 people present at baseline, we analysed 267,270: 94,675 assigned to vaccination only, 92,539 assigned to vaccination and behavioural change, and 80,056 assigned to non-intervention. Vaccine coverage was 65% in the vaccination only group and 66% in the vaccination and behavioural change group. Overall protective effectiveness was 37% (95% CI lower bound 18%; p=0·002) in the vaccination group and 45% (95% CI lower bound 24%; p=0·001) in the vaccination and behavioural change group. We recorded no vaccine-related serious adverse events.INTERPRETATION: Our findings provide the first indication of the effect of delivering an oral killed whole-cell cholera vaccine to poor urban populations with endemic cholera using routine government services and will help policy makers to formulate vaccination strategies to reduce the burden of severely dehydrating cholera in such populations.FUNDING: Bill & Melinda Gates Foundation.

medicine, general & internal
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

Suharyono,C Simanjuntak,H Totosudirjo,N Witham,N Punjabi,D Burr,K Sorenson,D.G Heppner,G Losonsky,J Clemens,Y.L Lim,S.S Wasserman,J Kaper,M.M Levine,A.R Rifai,S Cryz

DOI: https://doi.org/10.1016/0140-6736(92)92231-4

IF: 202.731

1992-09-01

The Lancet

Abstract:Oral vaccines offer great promise as public-health measures to prevent disease in less-developed countries. CVD 103-HgR, a genetically engineered, attenuated, Vibrio cholerae O1 strain has proved effective in industrialised countries. We have assessed the safety, immunogenicity, and excretion of this live cholera vaccine in children in north Jakarta, Indonesia. 412 children aged 5-9 years received single doses of 5 x 10(6), 5 x 10(7), 5 x 10(8), 5 x 10(9), or 1 x 10(10) colony forming units (CFU) of CVD 103-HgR or placebo (5 x 10(8) inactivated Escherichia coli K-12) with buffer. All doses were well tolerated. The 5 x 10(8) CFU dose, which is highly immunogenic in subjects in industrialised countries (greater than 90% seroconversion), elicited seroconversions of vibriocidal antibody in only 16% of Indonesian children. By contrast, a single 5 x 10(9) CFU dose of vaccine resulted in high rates (75% and 87%) of seroconversion with two different batches of vaccine. A batch prepared with a centrifugation step gave significantly higher geometric mean titres (16-fold increase over baseline) than did a batch in which there was a filtration step between fermentation and lyophilisation (10-fold increase over baseline). At a 5 x 10(9) CFU dose, CVD 103-HgR is well tolerated and highly immunogenic in Indonesian children and should therefore be further investigated for use as a one-dose live oral cholera vaccine in developing countries.

medicine, general & internal
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin

R E Black,M M Levine,M L Clements,C R Young,A M Svennerholm,J Holmgren

DOI: https://doi.org/10.1128/iai.55.5.1116-1120.1987

1987-05-01

Infection and Immunity

Abstract:Natural protection from cholera is associated with local intestinal antibacterial and antitoxic antibodies, which appear to act synergistically. Although current parenteral cholera vaccines offer insufficient protection, new vaccines administered orally have more promise. Killed Vibrio cholerae, alone or given with the B subunit of cholera toxin, was evaluated in adult volunteers. Vaccinees, who received three doses of either vaccine, and unvaccinated controls ingested 10(6) V. cholerae organisms to determine the protective efficacy of the vaccines. The combination vaccine provided 64% protection, and the whole vibrio vaccine given alone provided 56% protection. In addition, illnesses in vaccines were milder than those in controls, and both vaccines gave complete protection against more severe disease. This substantial level of protection against a dose of V. cholerae that caused cholera in nearly 90% of controls suggests that these vaccines might provide at least as high a level of protection if given to the population of an endemic area. Indeed, a field efficacy trial is underway in Bangladesh, and preliminary data indicate a protective efficacy of 85% for a killed whole vibrio plus B subunit vaccine similar to that tested in volunteers and an efficacy of 58% for the killed whole vibrio vaccine alone. Thus, the studies in human volunteers were successful in predicting the substantial protection afforded by the vaccines in a cholera endemic area.

immunology,infectious diseases
Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study

Andrew S Azman,Lucy A Parker,John Rumunu,Fisseha Tadesse,Francesco Grandesso,Lul L Deng,Richard Laku Lino,Bior K Bior,Michael Lasuba,Anne-Laure Page,Lameck Ontweka,Augusto E Llosa,Sandra Cohuet,Lorenzo Pezzoli,Dossou Vincent Sodjinou,Abdinasir Abubakar,Amanda K Debes,Allan M Mpairwe,Joseph F Wamala,Christine Jamet,Justin Lessler,David A Sack,Marie-Laure Quilici,Iza Ciglenecki,Francisco J Luquero

DOI: https://doi.org/10.1016/s2214-109x(16)30211-x

IF: 38.927

2016-11-01

The Lancet Global Health

Abstract:BACKGROUND: Oral cholera vaccines represent a new effective tool to fight cholera and are licensed as two-dose regimens with 2-4 weeks between doses. Evidence from previous studies suggests that a single dose of oral cholera vaccine might provide substantial direct protection against cholera. During a cholera outbreak in May, 2015, in Juba, South Sudan, the Ministry of Health, Médecins Sans Frontières, and partners engaged in the first field deployment of a single dose of oral cholera vaccine to enhance the outbreak response. We did a vaccine effectiveness study in conjunction with this large public health intervention.METHODS: We did a case-cohort study, combining information on the vaccination status and disease outcomes from a random cohort recruited from throughout the city of Juba with that from all the cases detected. Eligible cases were those aged 1 year or older on the first day of the vaccination campaign who sought care for diarrhoea at all three cholera treatment centres and seven rehydration posts throughout Juba. Confirmed cases were suspected cases who tested positive to PCR for Vibrio cholerae O1. We estimated the short-term protection (direct and indirect) conferred by one dose of cholera vaccine (Shanchol, Shantha Biotechnics, Hyderabad, India).FINDINGS: Between Aug 9, 2015, and Sept 29, 2015, we enrolled 87 individuals with suspected cholera, and an 898-person cohort from throughout Juba. Of the 87 individuals with suspected cholera, 34 were classified as cholera positive, 52 as cholera negative, and one had indeterminate results. Of the 858 cohort members who completed a follow-up visit, none developed clinical cholera during follow-up. The unadjusted single-dose vaccine effectiveness was 80·2% (95% CI 61·5-100·0) and after adjusting for potential confounders was 87·3% (70·2-100·0).INTERPRETATION: One dose of Shanchol was effective in preventing medically attended cholera in this study. These results support the use of a single-dose strategy in outbreaks in similar epidemiological settings.FUNDING: Médecins Sans Frontières.
Oral Cholera Vaccine Development and Use in Vietnam

Dang Duc Anh,Anna Lena Lopez,Hung Thi Mai Tran,Nguyen Van Cuong,Vu Dinh Thiem,Mohammad Ali,Jacqueline L. Deen,Lorenz von Seidlein,David A. Sack

DOI: https://doi.org/10.1371/journal.pmed.1001712

2014-09-02

PLoS Medicine

Abstract:Anna Lena Lopez and colleagues give an overview of the cholera situation in Vietnam and discuss how an oral cholera vaccine was developed and used as a component of a public health strategy against the disease. Please see later in the article for the Editors' Summary

medicine, general & internal
Killed oral cholera vaccines: history, development and implementation challenges

Anna Lena Lopez,Maria Liza Antoinette Gonzales,Josephine G Aldaba,G Balakrish Nair,Josephine G. Aldaba,G. Balakrish Nair

DOI: https://doi.org/10.1177/2051013614537819

2014-06-09

Therapeutic Advances in Vaccines

Abstract:Cholera is still a major global health problem, affecting mainly people living in unsanitary conditions and who are at risk for outbreaks of cholera. During the past decade, outbreaks are increasingly reported from more countries. From the early killed oral cholera vaccine, rapid improvements in vaccine development occurred as a result of a better understanding of the epidemiology of the disease, pathogenesis of cholera infection and immunity. The newer-generation oral killed cholera vaccines have been shown to be safe and effective in field trials conducted in cholera endemic areas. Likewise, they have been shown to be protective when used during outbreak settings. Aside from providing direct protection to vaccinated individuals, recent studies have demonstrated that these killed oral vaccines also confer indirect protection through herd immunity. Although new-generation oral cholera vaccines should not be considered in isolation from other preventive approaches in countries where they are most needed, especially improved water quality and sanitation, these vaccines serve as immediately available public health tools for preventing further morbidity and mortality from cholera. However, despite its availability for more than two decades, use of these vaccines has not been optimized. Although there are limitations of the currently available oral cholera vaccines, recent data show that the vaccines are safe, feasible to use even in difficult circumstances and able to provide protection in various settings. Clear identification of the areas and target population groups who will benefit from the use of the cholera vaccines will be required and strategies to facilitate accessibility and usage of these vaccines in these areas and population groups will need to be developed.

English Else
Oral Cholera Vaccine Protects Against Endemic Disease, Real Life Trial Shows:

Susan Mayor

DOI: https://doi.org/10.1136/bmj.h3730

2015-01-01

BMJ

Abstract:An oral cholera vaccine given as part of routine healthcare protects against severe cholera in children and adults in urban Bangladesh, where the disease is endemic, a real life trial of the vaccine has shown.1 The open label study, reported in the Lancet and funded by the Bill and Melinda Gates Foundation, included almost 270 000 people aged 1 and over living in the urban slums of Mirpur in Dhaka, Bangladesh. Researchers randomly assigned 90 geographical clusters of people to three groups: vaccination with a killed whole cell oral cholera vaccine (Shanchol); vaccination and behaviour change promoting handwashing …
Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis

Qifang Bi,Eva Ferreras,Lorenzo Pezzoli,Dominique Legros,Louise C Ivers,Kashmira Date,Firdausi Qadri,Laura Digilio,David A Sack,Mohammad Ali,Justin Lessler,Francisco J Luquero,Andrew S Azman,Oral Cholera Vaccine Working Group of The Global Task Force on Cholera Control,Philippe Cavailler,Kashmira Date,Nandini Sreenivasan,Helen Matzger,Francisco Luquero,Rebecca Grais,Lale Wiesner,Melissa Ko,Vanessa Rouzier,Corey Peak,Firdausi Qadri,Justine Landegger,Julia Lynch,Andrew Azman,David Sack,Myriam Henkens,Iza Ciglenecki,Louise Ivers,Emma Diggle,Mitchell Weiss,Alan Hinman,Kahindo Maina,Imran Mirza,Guillermo Gimeno,Myron Levine

DOI: https://doi.org/10.1016/s1473-3099(17)30359-6

IF: 71.421

2017-10-01

The Lancet Infectious Diseases

Abstract:BACKGROUND: Killed whole-cell oral cholera vaccines (kOCVs) are becoming a standard cholera control and prevention tool. However, vaccine efficacy and direct effectiveness estimates have varied, with differences in study design, location, follow-up duration, and vaccine composition posing challenges for public health decision making. We did a systematic review and meta-analysis to generate average estimates of kOCV efficacy and direct effectiveness from the available literature.METHODS: For this systematic review and meta-analysis, we searched PubMed, Embase, Scopus, and the Cochrane Review Library on July 9, 2016, and ISI Web of Science on July 11, 2016, for randomised controlled trials and observational studies that reported estimates of direct protection against medically attended confirmed cholera conferred by kOCVs. We included studies published on any date in English, Spanish, French, or Chinese. We extracted from the published reports the primary efficacy and effectiveness estimates from each study and also estimates according to number of vaccine doses, duration, and age group. The main study outcome was average efficacy and direct effectiveness of two kOCV doses, which we estimated with random-effect models. This study is registered with PROSPERO, number CRD42016048232.FINDINGS: Seven trials (with 695 patients with cholera) and six observational studies (217 patients with cholera) met the inclusion criteria, with an average two-dose efficacy of 58% (95% CI 42-69, I2=58%) and effectiveness of 76% (62-85, I2=0). Average two-dose efficacy in children younger than 5 years (30% [95% CI 15-42], I2=0%) was lower than in those 5 years or older (64% [58-70], I2=0%; p<0·0001). Two-dose efficacy estimates of kOCV were similar during the first 2 years after vaccination, with estimates of 56% (95% CI 42-66, I2=45%) in the first year and 59% (49-67, I2=0) in the second year. The efficacy reduced to 39% (13 to 57, I2=48%) in the third year, and 26% (-46 to 63, I2=74%) in the fourth year.INTERPRETATION: Two kOCV doses provide protection against cholera for at least 3 years. One kOCV dose provides at least short-term protection, which has important implications for outbreak management. kOCVs are effective tools for cholera control.FUNDING: The Bill & Melinda Gates Foundation.
Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study

Ahmed M Khatib,Mohammad Ali,Lorenz von Seidlein,Deok Ryun Kim,Ramadhan Hashim,Rita Reyburn,Benedikt Ley,Kamala Thriemer,Godwin Enwere,Raymond Hutubessy,Maria Teresa Aguado,Marie-Paule Kieny,Anna Lena Lopez,Thomas F Wierzba,Said Mohammed Ali,Abdul A Saleh,Asish K Mukhopadhyay,John Clemens,Mohamed Saleh Jiddawi,Jacqueline Deen

DOI: https://doi.org/10.1016/s1473-3099(12)70196-2

IF: 71.421

2012-11-01

The Lancet Infectious Diseases

Abstract:BACKGROUND: Zanzibar, in east Africa, has been severely and repeatedly affected by cholera since 1978. We assessed the effectiveness of oral cholera vaccination in high-risk populations in the archipelago to estimate the indirect (herd) protection conferred by the vaccine and direct vaccine effectiveness.METHODS: We offered two doses of a killed whole-cell B-subunit cholera vaccine to individuals aged 2 years and older in six rural and urban sites. To estimate vaccine direct protection, we compared the incidence of cholera between recipients and non-recipients using generalised estimating equations with the log link function while controlling for potential confounding variables. To estimate indirect effects, we used a geographic information systems approach and assessed the association between neighbourhood-level vaccine coverage and the risk for cholera in the non-vaccinated residents of that neighbourhood, after controlling for potential confounding variables. This study is registered with ClinicalTrials.gov, number NCT00709410.FINDINGS: Of 48,178 individuals eligible to receive the vaccine, 23,921 (50%) received two doses. Between February, 2009, and May, 2010, there was an outbreak of cholera, enabling us to assess vaccine effectiveness. The vaccine conferred 79% (95% CI 47-92) direct protection against cholera in participants who received two doses. Indirect (herd) protection was shown by a decrease in the risk for cholera of non-vaccinated residents within a household's neighbourhood as the vaccine coverage in that neighbourhood increased.INTERPRETATION: Our findings suggest that the oral cholera vaccine offers both direct and indirect (herd) protection in a sub-Saharan African setting. Mass oral cholera immunisation campaigns have the potential to provide not only protection for vaccinated individuals but also for the unvaccinated members of the community and should be strongly considered for wider use. Because this is an internationally-licensed vaccine, we could not undertake a randomised placebo-controlled trial, but the absence of vaccine effectiveness against non-cholera diarrhoea indicates that the noted protection against cholera could not be explained by bias.FUNDING: Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, and the South Korean Government.

infectious diseases
Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings

Amber Hsiao,Sachin N Desai,Vittal Mogasale,Jean-Louis Excler,Laura Digilio

DOI: https://doi.org/10.2471/blt.16.175166

IF: 13.831

2017-02-21

Bulletin of the World Health Organization

Abstract:Improving water and sanitation is the preferred choice for cholera control in the long-term. Nevertheless, vaccination is an available tool that has been shown to be a cost-effective option for cholera prevention in endemic countries or during outbreaks. In 2011 the first low-cost oral cholera vaccine for international use was given prequalification by the World Health Organization (WHO). To increase and prioritize use of the vaccine, WHO created a global stockpile in 2013 from which countries may request oral cholera vaccine for reactive campaigns. WHO has issued specific guidelines for applying for the vaccine, which was previously in short supply (despite prequalification for a second oral vaccine in 2015). The addition of a third WHO-prequalified oral cholera vaccine in 2016 is expected to increase the global stockpile considerably and alleviate supply issues. However, prioritization and best use of the vaccine (e.g. how, when and where to use) will remain challenges. We describe 12 past oral cholera vaccine campaigns, conducted in settings with varying burdens of cholera. These case studies illustrate three key challenges faced in the use of the oral cholera vaccines: regulatory hurdles, cold chain logistics and vaccine coverage and uptake. To pave the way for the introduction of current and future oral cholera vaccines, we discuss operational challenges and make recommendations for future research with respect to each of these challenges.

public, environmental & occupational health
Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected)

Patricia M Graves,Jonathan J Deeks,Vittorio Demicheli,Tom Jefferson

DOI: https://doi.org/10.1002/14651858.cd000974.pub2

IF: 8.4

2010-08-08

Cochrane Database of Systematic Reviews

Abstract:BACKGROUND: Injected cholera vaccines are rarely used today, although they may have some benefit. It is valuable to summarize the evidence for effectiveness of injected cholera vaccines for comparison with newer oral vaccines (subject of a separate Cochrane Review).OBJECTIVES: To evaluate killed whole cell (KWC) cholera vaccines and other inactive subunit vaccines (administered by injection) for preventing cholera and death, and to evaluate the adverse effects.SEARCH STRATEGY: In September 2008, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2008, Issue 3), EMBASE, and LILACS. We also searched reference lists and handsearched the journal Vaccine up to 1997.SELECTION CRITERIA: Randomized and quasi-randomized controlled trials comparing injected cholera vaccines (KWC or other inactive subunit) with placebo, control vaccines, or no intervention in adults and children irrespective of immune status or special risk category.DATA COLLECTION AND ANALYSIS: Two authors extracted data and assessed trial methodological quality independently. Dichotomous data were reported using the risk ratio (RR) with 95% confidence intervals (CI). Vaccine efficacies were also calculated (% vaccine efficacy = (1-RR) x 100%).MAIN RESULTS: Sixteen trials, involving over one million adults, children and infants, fulfilled the inclusion criteria. Twenty-four comparisons reported on vaccine efficacy (cholera cases and/or deaths) and 11 comparisons considered adverse effects (nine reported on both). Compared to placebo, vaccinees had a reduced risk of death from cholera (RR 0.49, 95% CI 0.25 to 0.93; 837,442 participants) and a reduced risk of contracting cholera at 12 months (RR 0.52, 95% CI 0.42 to 0.65, random-effects model; 1,512,573 participants). This translates to an efficacy of 48%, 95% confidence interval 35% to 58%. Significant protection lasted for two years, even after only a single dose, and for three years with an annual booster. Children over five years and adults were protected for up to three years, while children under five years were protected for up to a year. Injected cholera vaccines were associated with more systemic and local adverse effects compared to placebo, but these were not severe or life-threatening.AUTHORS' CONCLUSIONS: Injected cholera vaccines appear to be safe and relatively more effective than usually realized. Protection against cholera persists for up to two years following a single dose of vaccine, and for three years with an annual booster. However, they have been superseded by oral vaccines.

medicine, general & internal
Considerations around the introduction of a cholera vaccine in Bangladesh

Christopher B. Nelson,Vittal Mogasale,Tajul Islam A. Bari,John D. Clemens

DOI: https://doi.org/10.1016/j.vaccine.2014.05.028

IF: 4.169

2014-12-01

Vaccine

Abstract:Cholera is an endemic and epidemic disease in Bangladesh. On 3 March 2013, a meeting on cholera and cholera vaccination in Bangladesh was convened by the Foundation Mérieux jointly with the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B). The purpose of the meeting was to discuss the investment case for cholera vaccination as a complimentary control and prevention strategy. The performance of a new low cost oral cholera vaccine, Shanchol™, used in recent trials in Bangladesh, was also reviewed in the context of a potential large-scale public-sector vaccination program. Findings showed the oral vaccine to be highly cost-effective when targeting ages 1-14 y, and cost-effective when targeting ages 1+y, in high-burden/high-risk districts. Other vaccination strategies targeting urban slums and rural areas without improved water were found to be cost-effective. Regardless of cost-effectiveness (value), the budget impact (affordability) will be an important determinant of which target population and vaccination strategy is selected. Most importantly, adequate vaccine supply for the proposed vaccination programs must be addressed in the context of global efforts to establish a cholera vaccine stockpile and supply other control and prevention efforts.

immunology,medicine, research & experimental
The Costs and Cost-Effectiveness of a Two-Dose Oral Cholera Vaccination Campaign: A Case Study in a Refugee Camp Setting in Thailand

Aaron S. Wallace,Kashmira Date,Sarah W. Pallas,Nuttapong Wongjindanon,Christina R. Phares,Taiwo Abimbola

DOI: https://doi.org/10.3390/vaccines12111235

2024-10-31

Vaccines

Abstract:Oral cholera vaccination (OCV) campaigns are increasingly used to prevent cholera outbreaks; however, little is known about their cost-effectiveness in refugee camps. We conducted a cost-effectiveness analysis of a pre-emptive OCV campaign in the Maela refugee camp in Thailand, where outbreaks occurred with an annual incidence rate (IR) of up to 10.7 cases per 1000. Data were collected via health sector records and interviews and household interviews. In the base-case scenario comparing the OCV campaign with no campaign, we estimated the campaign effect on the cholera IR and case fatality rate (CFR: 0.09%) from a static cohort model and calculated incremental cost-effectiveness ratios for the outcomes of death, disability-adjusted life-years (DALYs), and cases averted. In sensitivity analyses, we varied the CFR and IR. The household economic cost of illness was USD 21, and the health sector economic cost of illness was USD 51 per case. The OCV campaign economic cost was USD 289,561, 42% attributable to vaccine costs and 58% to service delivery costs. In our base case, the incremental cost was USD 1.9 million per death averted, USD 1745 per case averted, and USD 69,892 per DALY averted. Sensitivity analyses that increased the CFR to 0.35% or the IR to 10.4 cases per 1000 resulted in a cost per DALY of USD 15,666. The low multi-year average CFR and incidence of the cholera outbreaks in the Maela camp were key factors associated with the high cost per DALY averted. However, the sensitivity analyses indicated higher cost-effectiveness in a setting with a higher CFR or cholera incidence, indicating when to consider campaign use to reduce the outbreak risk.

immunology,medicine, research & experimental
Controlling Endemic Cholera with Oral Vaccines

Ira M Longini,Azhar Nizam,Mohammad Ali,Mohammad Yunus,Neeta Shenvi,John D Clemens

DOI: https://doi.org/10.1371/journal.pmed.0040336

2007-11-27

PLoS Medicine

Abstract:BACKGROUND: Although advances in rehydration therapy have made cholera a treatable disease with low case-fatality in settings with appropriate medical care, cholera continues to impose considerable mortality in the world's most impoverished populations. Internationally licensed, killed whole-cell based oral cholera vaccines (OCVs) have been available for over a decade, but have not been used for the control of cholera. Recently, these vaccines were shown to confer significant levels of herd protection, suggesting that the protective potential of these vaccines has been underestimated and that these vaccines may be highly effective in cholera control when deployed in mass immunization programs. We used a large-scale stochastic simulation model to investigate the possibility of controlling endemic cholera with OCVs.METHODS AND FINDINGS: We construct a large-scale, stochastic cholera transmission model of Matlab, Bangladesh. We find that cholera transmission could be controlled in endemic areas with 50% coverage with OCVs. At this level of coverage, the model predicts that there would be an 89% (95% confidence interval [CI] 72%-98%) reduction in cholera cases among the unvaccinated, and a 93% (95% CI 82%-99%) reduction overall in the entire population. Even a more modest coverage of 30% would result in a 76% (95% CI 44%-95%) reduction in cholera incidence for the population area covered. For populations that have less natural immunity than the population of Matlab, 70% coverage would probably be necessary for cholera control, i.e., an annual incidence rate of < or = 1 case per 1,000 people in the population.CONCLUSIONS: Endemic cholera could be reduced to an annual incidence rate of < or = 1 case per 1,000 people in endemic areas with biennial vaccination with OCVs if coverage could reach 50%-70% depending on the level of prior immunity in the population. These vaccination efforts could be targeted with careful use of ecological data.

medicine, general & internal
Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

Emily Richie,Narain H Punjabi,Yuwono Sidharta,Kenny Peetosutan,Melanie Sukandar,Steven S Wasserman,Murad Lesmana,Ferry Wangsasaputra,Sri Pandam,Myron M Levine,Peter O’Hanley,Stanley J Cryz,Cyrus H Simanjuntak,E Richie

DOI: https://doi.org/10.1016/s0264-410x(00)00006-2

IF: 4.169

2000-05-01

Vaccine

Abstract:A randomized, double-blind, placebo-controlled efficacy trial of one dose of CVD 103-HgR live oral cholera vaccine was performed in Indonesia from 1993 to 1997. 67,508 persons aged 2-41 years ingested vaccine or placebo and were followed for four years, detecting cholera cases using hospital-based surveillance. A nested reactogenicity study (538 vaccinees, 535 controls) revealed no vaccine-attributable side effects. A nested immunogenicity study (N=657) showed vibriocidal seroresponses in 64-70% of vaccinees vs 1-2% of controls. Cholera incidence was lower than expected. 103 cases of Vibrio cholerae O1 El Tor diarrhea were detected, 93 evaluable for vaccine efficacy (43 vaccine, 50 placebo; efficacy=14%). A suggestion of protection was observed among persons with blood group O [P=0.12]. Only seven cases occurred within six months of vaccination, precluding assessment of short-term efficacy. In Jakarta, single-dose CVD 103-HgR did not confer long-term protection. Short-term protection from a single-dose and long-term protection from two doses have yet to be studied.

immunology,medicine, research & experimental
Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study

Espoir Bwenge Malembaka,Patrick Musole Bugeme,Chloe Hutchins,Hanmeng Xu,Juan Dent Hulse,Maya N Demby,Karin Gallandat,Jaime Mufitini Saidi,Baron Bashige Rumedeka,Moïse Itongwa,Esperance Tshiwedi-Tsilabia,Faida Kitoga,Tavia Bodisa-Matamu,Hugo Kavunga-Membo,Justin Bengehya,Jean-Claude Kulondwa,Amanda K Debes,Nagède Taty,Elizabeth C Lee,Octavie Lunguya,Justin Lessler,Daniel T Leung,Oliver Cumming,Placide Welo Okitayemba,Daniel Mukadi-Bamuleka,Jackie Knee,Andrew S Azman

DOI: https://doi.org/10.1016/s1473-3099(23)00742-9

IF: 71.421

2024-01-25

The Lancet Infectious Diseases

Abstract:Summary Background A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is sparse evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo, resulting in largely single-dose coverage. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus in this high-burden setting. Methods In this matched case-control study, we recruited individuals with medically attended confirmed cholera in the two cholera treatment facilities in the city of Uvira. The control group consisted of age-matched, sex-matched, and neighbourhood-matched community individuals. We recruited across two distinct periods: Oct 14, 2021, to March 10, 2022 (12–17 months after vaccination), and Nov 21, 2022, to Oct 18, 2023 (24–36 months after vaccination). Study staff administered structured questionnaires to all participants to capture demographics, household conditions, potential confounding variables, and vaccination status. The odds of vaccination for the case and control groups were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness. Findings We enrolled 658 individuals with confirmed cholera and 2274 matched individuals for the control group. 99 (15·1%) individuals in the case group were younger than 5 years at the time of vaccination. The adjusted single-dose vaccine effectiveness was 52·7% (95% CI 31·4 to 67·4) 12–17 months after vaccination and 44·7% (24·8 to 59·4) 24–36 months after vaccination. Although protection in the first 12–17 months after vaccination was similar for children aged 1–4 years and older individuals, the estimate of protection in children aged 1–4 years appeared to wane during the third year after vaccination (adjusted vaccine effectiveness 32·9%, 95% CI –30·7 to 65·5), with CIs spanning the null. Interpretation A single dose of Euvichol-Plus provided substantial protection against medically attended cholera for at least 36 months after vaccination in this cholera-endemic setting. Although the evidence provides support for similar levels of protection in young children and others in the short term, protection among children younger than 5 years might wane significantly during the third year after vaccination. Funding Wellcome Trust and Gavi, the Vaccine Alliance.

infectious diseases

Transcriptional regulation by iron of genes encoding iron- and manganese-superoxide dismutases from Pseudomonas putida.

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

Efficacy of a Low-Cost, Inactivated Whole-Cell Oral Cholera Vaccine: Results from 3 Years of Follow-Up of a Randomized, Controlled Trial

Effectiveness of an oral cholera vaccine campaign to prevent clinically-significant cholera in Odisha State, India

Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial

Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children

Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin

Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study

Oral Cholera Vaccine Development and Use in Vietnam

Killed oral cholera vaccines: history, development and implementation challenges

Oral Cholera Vaccine Protects Against Endemic Disease, Real Life Trial Shows:

Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis

Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study

Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings

Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected)

Considerations around the introduction of a cholera vaccine in Bangladesh

The Costs and Cost-Effectiveness of a Two-Dose Oral Cholera Vaccination Campaign: A Case Study in a Refugee Camp Setting in Thailand

Controlling Endemic Cholera with Oral Vaccines

Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area

Effectiveness of one dose of killed oral cholera vaccine in an endemic community in the Democratic Republic of the Congo: a matched case-control study